• / Free eNewsletters & Magazine
  • / My Account
Home>Chi-Med Highlights Oral Presentations at CSCO Annual Meeting

Chi-Med Highlights Oral Presentations at CSCO Annual Meeting

Chi-Med Highlights Oral Presentations at CSCO Annual Meeting

09/29/2017

Chi-Med Highlights Oral Presentations at CSCO Annual Meeting

– Three oral presentations given at CSCO for fruquintinib, savolitinib and theliatinib –

– Plenary keynote presentation for FRESCO Phase III trial details analysis showing consistent survival benefit in all key subgroups –

Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced that new clinical data on three of its novel tyrosine kinase inhibitors, fruquintinib, savolitinib and theliatinib, were presented at the 20th Annual Meeting of the Chinese Society of Clinical Oncology (“CSCO”), held in Xiamen, China, from September 26 to 30, 2017.

The three oral presentations were as follows:

Fruquintinib: Further in-depth results from FRESCO

Session:   Plenary Keynote Presentation
Presenter: Shukui Qin
Date: Wednesday, September 27
Presentation Slides:

www.chi-med.com/csco-2017-fresco/

FRESCO is the Phase III trial assessing fruquintinib in patients with colorectal cancer (“CRC”) in China. Overall results presented earlier at the American Society of Clinical Oncology annual meeting in June 2017 showed that the trial met all primary and secondary efficacy endpoints. Fruquintinib is a novel vascular endothelial growth factor (“VEGF”) receptor kinase inhibitor.

©2017 Morningstar Advisor. All right reserved.